Scinovex
article Open AccessTop 1% cited

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Journal of the American Academy of Dermatology · 2015 · Vol. 73(1) · pp. 37–49
Kim PappKristian ReichCraig L. LeonardiLeon KircikSergio ChimentiRichard G. LangleyChiaChi HuRandall M. StevensRobert M. DayKenneth B. GordonNeil J. KormanC.E.M. Griffiths
Psoriasis: Treatment and PathogenesisPhosphodiesterase function and regulationAsthma and respiratory diseasesApremilastMedicinePsoriasisPlaque psoriasisRandomized controlled trialDermatologyPhosphodiesterase inhibitorPhosphodiesteraseInternal medicinePharmacology

MeSH terms

Administration, OralDouble-Blind MethodFemaleHumansMaleMiddle AgedPsoriasisSeverity of Illness IndexThalidomidePhosphodiesterase 4 Inhibitors

Funding

  • Abbott Laboratories
  • Amgen
  • Eli Lilly and Company
  • Pfizer
  • Astellas Pharma US
  • GlaxoSmithKline
  • Merck
  • Novartis
  • 3M
  • Biogen Idec
  • Celgene
  • AbbVie
  • National Institute for Health and Care Research
  • Galderma
  • LEO Pharma
  • Genentech
  • Johnson and Johnson
  • Allergan
  • Merck Sharp and Dohme
  • Sandoz
  • Janssen Pharmaceuticals
Citations
659
FWCI
28.37
field-weighted impact
References
16
Percentile
100%
vs. same field & year
Citations per year
References
Guidelines of care for the management of psoriasis and psoriatic arthritis
Journal of the American Academy of Dermatology · 2008 · 765 citations
Guidelines of care for the management of psoriasis and psoriatic arthritis
Journal of the American Academy of Dermatology · 2008 · 1,202 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.